Eli Lilly upped its guidance for 2019 after posting strong third quarter results, as more recently released drugs offset sales lost as former erectile dysfunction blockbuster Cialis lost pa
The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.